{"type":"rich","version":"1.0","provider_name":"Transistor","provider_url":"https://transistor.fm","author_name":"NextGen Patient Voice","title":"Unlocking Asthma Relief: The AIRLYMPUS Study's Quest for Better Breathing Solutions","html":"","width":"100%","height":180,"duration":364,"description":"The AIRLYMPUS Study is investigating a new drug for adults with asthma to see if it can improve breathing, alleviate symptoms, and reduce future attacks when added to standard therapy. Eligible participants are aged 18-80, have had asthma for at least a year, and are on daily treatment.\nThe BLU-808-1201 study is seeking participants with chronic spontaneous urticaria who still experience symptoms despite antihistamine use. This study involves an oral tablet, lab tests, and monitoring, with reimbursement for expenses.\nA Phase 2b trial for EVO756, an investigational therapy for atopic dermatitis, is enrolling adults. This study targets MRGPRX2, a key itch and inflammation driver, offering a potential new path for eczema relief.\nAsthma can be dormant for years but may return due to various factors. It's crucial to manage asthma with prescribed medications and avoid triggers.\nThe Atopic Dermatitis in America study by AAFA and NEA highlights that 7.3% of U.S. adults have AD, with 40% experiencing moderate to severe symptoms. The study aims to understand the prevalence, severity, and burden of AD.\nLucid Health Solutions\nEmbedding the patient, caregiver and provider perspective into every decision that shapes health outcomes\n https://www.lucidhealthsolutions.com\n\n\nLucid Health Solutions\nEmbedding the patient, caregiver and provider perspective into every decision that shapes health outcomes\n https://www.lucidhealthsolutions.com","thumbnail_url":"https://img.transistorcdn.com/AhLc2JOSG6Gbfo9Op45fbD4Ktz4gMRB4dyiv7oHUDi0/rs:fill:0:0:1/w:400/h:400/q:60/mb:500000/aHR0cHM6Ly9pbWct/dXBsb2FkLXByb2R1/Y3Rpb24udHJhbnNp/c3Rvci5mbS9mYzhi/YzIzMmE2ZWFjMjU0/NTEyZDBiYzE0NWFm/NDY5NS5wbmc.webp","thumbnail_width":300,"thumbnail_height":300}